Using a molecule designed to overcome a roadblock formed by a common type of genetic flaw, researchers at the University of Wisconsin — Madison have made
progress towards novel molecular treatments for Friedreich's ataxia — a rare but fatal disorder —
in the
laboratory dish and
in animals.